HomeCompareJRVS vs JNJ

JRVS vs JNJ: Dividend Comparison 2026

JRVS yields 160.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JRVS wins by $34.83M in total portfolio value
10 years
JRVS
JRVS
● Live price
160.00%
Share price
$1.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.86M
Annual income
$15,634,271.53
Full JRVS calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — JRVS vs JNJ

📍 JRVS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJRVSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JRVS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JRVS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JRVS
Annual income on $10K today (after 15% tax)
$13,600.00/yr
After 10yr DRIP, annual income (after tax)
$13,289,130.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JRVS beats the other by $13,285,144.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JRVS + JNJ for your $10,000?

JRVS: 50%JNJ: 50%
100% JNJ50/50100% JRVS
Portfolio after 10yr
$17.44M
Annual income
$7,819,480.46/yr
Blended yield
44.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JRVS
No analyst data
Altman Z
-17.3
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JRVS buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJRVSJNJ
Forward yield160.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$34.86M$30.3K
Annual income after 10y$15,634,271.53$4,689.40
Total dividends collected$32.40M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JRVS vs JNJ ($10,000, DRIP)

YearJRVS PortfolioJRVS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$26,700$16,000.00$10,592$272.30+$16.1KJRVS
2$68,494$39,925.23$11,289$357.73+$57.2KJRVS
3$169,010$95,720.83$12,123$472.89+$156.9KJRVS
4$401,580$220,739.56$13,141$629.86+$388.4KJRVS
5$919,872$490,181.40$14,408$846.81+$905.5KJRVS
6$2,033,632$1,049,369.50$16,021$1,151.60+$2.02MJRVS
7$4,344,139$2,168,152.23$18,122$1,588.22+$4.33MJRVS
8$8,976,727$4,328,498.22$20,930$2,228.20+$8.96MJRVS
9$17,964,357$8,359,258.83$24,792$3,191.91+$17.94MJRVS
10$34,856,133$15,634,271.53$30,274$4,689.40+$34.83MJRVS

JRVS vs JNJ: Complete Analysis 2026

JRVSStock

iMine Corporation operates in the real estate sector. It buys and develops real estate properties for sale or rent to low-income individuals and families. The company was formerly known as Diamante Minerals, Inc. and changed its name to iMine Corporation in March 2018. iMine Corporation is based in Miami, Florida.

Full JRVS Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JRVS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JRVS vs SCHDJRVS vs JEPIJRVS vs OJRVS vs KOJRVS vs MAINJRVS vs ABBVJRVS vs MRKJRVS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.